AtriCure (ATRC) Stock Overview
Develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ATRC Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
AtriCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.24 |
| 52 Week High | US$43.11 |
| 52 Week Low | US$27.64 |
| Beta | 1.59 |
| 1 Month Change | 6.37% |
| 3 Month Change | 27.27% |
| 1 Year Change | 29.35% |
| 3 Year Change | 1.39% |
| 5 Year Change | -1.90% |
| Change since IPO | 164.49% |
Recent News & Updates
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 01
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Jul 08Recent updates
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 01AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Jul 08AtriCure: Profits And Operating Leverage Are Needed Here
Jun 26AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
May 01Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Apr 04
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
Jan 22Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Jan 15Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 24A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Nov 06US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
Nov 01Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Oct 31AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Oct 02Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
Sep 06Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
Aug 02AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
Jul 18AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
May 30Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
Apr 04Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Mar 14Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
Jan 21Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Nov 29AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 27Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Aug 02AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion
Jun 15Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
Apr 14Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)
Mar 02What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?
Feb 09Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Dec 28Shareholder Returns
| ATRC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.9% | -2.1% | -1.2% |
| 1Y | 29.4% | -2.8% | 15.1% |
Return vs Industry: ATRC exceeded the US Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: ATRC exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| ATRC volatility | |
|---|---|
| ATRC Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ATRC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ATRC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,300 | Mike Carrel | www.atricure.com |
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters.
AtriCure, Inc. Fundamentals Summary
| ATRC fundamental statistics | |
|---|---|
| Market cap | US$1.85b |
| Earnings (TTM) | -US$36.36m |
| Revenue (TTM) | US$499.95m |
Is ATRC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRC income statement (TTM) | |
|---|---|
| Revenue | US$499.95m |
| Cost of Revenue | US$126.42m |
| Gross Profit | US$373.52m |
| Other Expenses | US$409.88m |
| Earnings | -US$36.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 74.71% |
| Net Profit Margin | -7.27% |
| Debt/Equity Ratio | 13.3% |
How did ATRC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 01:27 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AtriCure, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |